Deliver Your News to the World

Commercially Available Assay Kits for 5mC-Hydroxylase TET Studies Have Been Developed by Epigentek


NEW YORK, August 11 – The research and development team at Epigentek has developed a new method to measure the activity and inhibition of ten-eleven translocation (TET) family of 5mC-hydroxylase enzymes via a straightforward detection of TET-converted products. This method is incorporated into commercially available kits under the Epigenase(TM) brand to provide ultra-sensitive assays for the measurement of TET hydroxylase activity or inhibition.

The TET family of 5-mC hydroxylases includes TET1, TET2, and TET3, and plays a critical role in DNA demethylation by binding to CpG-rich regions to prevent unwanted DNA methyltransferase activity. It converts 5mC (5-methylcytosine) to 5hmC (5-hydroxylmethylcytosine) and further to 5caC (5-carboxylcytosine) through hydroxylase activity.

In addition, TET1 has been shown to have dual functions in transcription activation and repression by binding different target genes in ES cells. TET1 is also a fusion partner of the MLL gene in acute myeloid leukemia and is considered as an oncoprotein. TET2 is found to be frequently mutated in leukemia and considered to act as a tumor suppressor. TET3 has been demonstrated to play a unique role in DNA methylation reprogramming processes in the mammalian zygote.

Thus, activating tumor suppressor TET enzymes such as TET2 or inhibiting oncoprotein TET enzymes such as TET1 has considerable significance in benefiting cancer diagnositcs and in developing new target-based cancer therapeutics.

Because there are a lack of methods currently available for efficiently and practically detecting TET hydroxylase activity/inhibition using both nuclear extracts and purified enzymes, the Epigenase(TM) product’s 96-stripwell microplate format and 3.5-hour assay time is particularly useful for high throughput screening in discovering inhibitors or activators of TET as potential therapeutic agents.

For further information on our DNA methylation/demethylation products, please visit

About Epigentek Group Inc.
Epigentek is a leading biotechnology company that focuses on developing and providing innovative technologies and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit our informative website at



This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.